Upgrade to SI Premium - Free Trial

Form 3 CASI Pharmaceuticals, For: Mar 18 Filed by: He Wei-Wu

March 18, 2026 7:06 PM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
He Wei-Wu
(Last) (First) (Middle)
1701-1702, CHINA CENTRAL OFFICE TOWER 1,
NO. 81 JIANGUO ROAD CHAOYANG DISTRICT
(Street)
BEIJING 100025
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026 		3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Share 1,910,550
D
Ordinary Share 44,107
I
See Footnote (1)
Ordinary Share 753,234
I
See Footnote (2)
Ordinary Share 300,000
I
See Footnote (3)
Ordinary Share 100,000
I
See Footnote (4)
Ordinary Share 637,644
I
See Footnote (5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Convertible Note (right to convert) 03/28/2026 12/26/2028 Ordinary Share (6) (6) I See Footnote (7)
Convertible Note (right to convert) 04/10/2026 01/08/2029 Ordinary Share (6) (6) I See Footnote (7)
Convertible Note (right to convert) 05/21/2026 02/18/2029 Ordinary Share (6) (6) I See Footnote (7)
Option (right to buy) 05/12/2025 05/12/2033 Ordinary Share 20,000 1.93 D
Option (right to buy) 05/12/2026 05/12/2033 Ordinary Share 20,000 1.93 D
Option (right to buy) 04/14/2023 04/27/2031 Ordinary Share 100,000 1.93 D
Option (right to buy) 04/27/2025 04/27/2031 Ordinary Share 100,000 1.93 D
Option (right to buy) (8) 04/27/2031 Ordinary Share 300,000 1.93 D
Explanation of Responses:
1. Held by Emerging Technology Partners, LLC, a Delaware limited liability company, of which Dr. He is founder and managing partner.
2. Held by ETP Global Fund. L.P., a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.
3. Held by ETP BioHealth III Fund, L.P., a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.
4. Held by HE Family GRAT, a grantor retained annuity trust organized under the law of Nevada for the benefit of Dr. Wei-Wu He's family members, and Dr. Wei-Wu He is the trustee of HE Family GRAT.
5. Held by Huiying Memorial Foundation, a 501(c)(3) private family foundation under the law of Delaware and Dr. He is a member of the board of trustees and an officer of the Huiying Memorial Foundation. Dr. He does not participate in the investment decisions of the Foundation with respect to CASI's ordinary shares and disclaims beneficial ownership of CASI's ordinary shares held by Huiying Memorial Foundation.
6. The conversion price is volume weighted average closing price of the issuer's Ordinary Shares during the five consecutive trading days immediately preceding the date of conversion notice by ETP Global Fund III L.P. In no event shall the conversion price be higher than US $2 per Ordinary Share or lower than US $1 per Ordinary Share. Pursuant to the trading price of the issuer's ordinary shares as of March 17, 2026, the amount of ordinary shares convertible under each Note is 5,000,000 (without considering accrued but unpaid interest).
7. Held by ETP Global Fund III L.P., , a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.
8. Performance based options granted and exercisable upon achievement.
/s/ Wei-Wu He 03/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings